Overview

Ocular Hypotensive Efficacy of AR-102

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
Antihypertensive Agents
Ophthalmic Solutions
Pharmaceutical Solutions